These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18195093)

  • 1. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.
    Bonig H; Wundes A; Chang KH; Lucas S; Papayannopoulou T
    Blood; 2008 Apr; 111(7):3439-41. PubMed ID: 18195093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
    Jing D; Oelschlaegel U; Ordemann R; Hölig K; Ehninger G; Reichmann H; Ziemssen T; Bornhäuser M
    Bone Marrow Transplant; 2010 Oct; 45(10):1489-96. PubMed ID: 20098455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.
    Zohren F; Toutzaris D; Klärner V; Hartung HP; Kieseier B; Haas R
    Blood; 2008 Apr; 111(7):3893-5. PubMed ID: 18235044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors.
    Vuaillat C; Androdias G; Davoust N; Nataf S
    Blood; 2008 Jul; 112(1):208-9; author reply 209-10. PubMed ID: 18574042
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.
    Mattoscio M; Nicholas R; Sormani MP; Malik O; Lee JS; Waldman AD; Dazzi F; Muraro PA
    Neurology; 2015 Apr; 84(14):1473-82. PubMed ID: 25762712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes.
    Lesesve JF; Debouverie M; Decarvalho Bittencourt M; Béné MC
    Bone Marrow Transplant; 2011 Nov; 46(11):1489-91. PubMed ID: 21243032
    [No Abstract]   [Full Text] [Related]  

  • 7. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
    Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
    PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells.
    Christ O; Kronenwett R; Haas R; Zöller M
    Exp Hematol; 2001 Mar; 29(3):380-90. PubMed ID: 11274767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of anti-CD49d monoclonal antibody on mobilization of CD34 positive cell into peripheral blood in mice].
    Liu CF; Du ZM; Zhagn YK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Feb; 12(1):59-62. PubMed ID: 14989770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model.
    Häusler D; Nessler S; Kruse N; Brück W; Metz I
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):814-31. PubMed ID: 25641089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxicity profile of natalizumab.
    Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Natalizumab: an antibody targeting α4-integrin].
    Nakahara J
    Brain Nerve; 2014 Oct; 66(10):1149-58. PubMed ID: 25296869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
    Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
    Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
    Saure C; Warnke C; Zohren F; Schroeder T; Bruns I; Cadeddu RP; Weigelt C; Fischer U; Kobbe G; Hartung HP; Adams O; Kieseier BC; Haas R
    Arch Neurol; 2011 Nov; 68(11):1428-31. PubMed ID: 22084125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization.
    Papayannopoulou T; Priestley GV; Bonig H; Nakamoto B
    Blood; 2003 Jun; 101(12):4739-47. PubMed ID: 12595315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
    Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
    PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of natalizumab in hematopoietic stem cell mobilization.
    Neumann F; Zohren F; Haas R
    Expert Opin Biol Ther; 2009 Aug; 9(8):1099-106. PubMed ID: 19566481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.